Indiana Biosciences Research Institute (IBRI)

IBRI is a first-in-class translational medicine institute dedicated to advancing life sciences in the race to eliminate disease and improve human health and life. Turn up the volume to learn more! #IBRI #biosciences #lifesciences #futureofhealth #globalimpact

INSIDE IBRI: IMPACT GIVING Indiana Biosciences Research Institute (IBRI) was built to solve big problems. We do that work every day, and we measure our progress. Yes, aspects of our scientific work aimed at tackling the biggest challenges may start small or seem esoteric, but this work is not abstract. Each day what happens in our labs is carefully documented, data is generated, and the work matters to people around the world. Curing diseases is a series of problems that urgently need to be solved, and we are ever mindful that every day counts. Our goal at IBRI is continuous impact. So we measure our work and hold ourselves accountable to progress. Transparency and monitoring is a part of IBRI institutional culture and is foundational to the launch of our new impact giving campaign. In the coming year, IBRI will be engaging with donors here in Indiana and around the world to secure funds for impact giving. Whether in Indianapolis, Los Angeles, or London, conversations with donors are almost always specific. Givers are spurred toward generosity for many reasons, and often there is a personal connection. For those givers, cures cannot come fast enough. By encouraging donors to choose targets for support, we can fuel momentum and track the impact of these gifts. It’s a model that makes sense in an increasingly complex research ecosystem. Your support goes directly toward accelerating discoveries, not navigating bureaucracy. When it comes to rare diseases, particularly pediatric cancers, time matters most of all. For these illnesses that impact a relatively small number of children, and their families, hope and help are vital because most research funding is pegged to population size. Historically, diseases which may be statistically marginal are underfunded, and targeted giving can vault over that barrier, adding more resources with more direct funding. My job is to make sure that every potential donor, everywhere, is aware that as IBRI continues to unlock cures, the opportunities for direct impact are here, and now. #IBRI #impactgiving #philanthropy

Exciting news! The IBRI Life Science Lab podcast, with host Ari Landon, PhD, MBA, is set to launch in January 2026. Stay tuned for insightful conversations at the intersection of science, innovation, and impact! #IBRI #podcast #lifesciencelab

Indiana Biosciences Research Institute (IBRI) is proud to sponsor the IBJ Media Central Indiana Innovate Luncheon on December 11, featuring Governor Mike Braun, Office of the Governor of Indiana, and honoring Dennis Bland, President of the Center for Leadership Development—an Indianapolis nonprofit dedicated to empowering African American youth. We’re honored to support this celebration of leadership and impact in our community. #IBRI #IBJ #centralindiana #indianapolis #innovate #philanthropy

C&EN’s annual 10 Start-Ups to Watch 2025 issue celebrates emerging companies using the central science to make the world better — and build bold new businesses along the way. Congratulations to Syndeio Biosciences and CEO Derek A Small on this well-deserved recognition! Syndeio, a member of the Indiana Biosciences Research Institute (IBRI) Future Legends Lab, is pioneering new approaches to target the brain’s connections. Their focus on the synapse may hold the key to unlocking transformative treatments for major depressive disorder and dementia. Exciting progress from an exciting team — well done, Syndeio! To read more, please visit https://lnkd.in/gvCyntK2. American Chemical Society ACS Media Group #IBRI #syndeio #futurelegendslab #majordepressivedisorder #dementia #lifesciences #biosciences

FOR IMMEDIATE RELEASE Indiana Biosciences Research Institute Announces Research Partnership with Eli Lilly and Company Indianapolis (November 17, 2025) — The Indiana Biosciences Research Institute (IBRI) is pleased to announce a new research partnership with Eli Lilly and Company (Lilly) focused on advancing the understanding of neural mechanisms that regulate energy balance and body weight. The three-year initiative will include a multidisciplinary team of investigators at the IBRI led by Jonathan Douros, PhD, in collaboration with Stephanie Mowery, PhD and Patrick Knerr, PhD. The study will examine the molecular pharmacology of amylin receptors in specific neuronal populations. These receptors are key targets for emerging obesity treatments. “This project addresses a critical gap in our understanding of how central amylin signaling pathways influence metabolic and other therapeutic outcomes,” said Dr. Douros. “Our goal is to define amylin receptor function within specific areas of the brain.” To access the full press release, please visit https://lnkd.in/g6A8hQgZ. #IBRI #Lilly #lifesciences #molecularpharmacology #amylinreceptors #obesity